Radius Health Inc. won FDA approval, albeit mildly delayed, of injected Tymlos for postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
Recognizing the conundrum that is the Biologics Price Competition and Innovation Act (BPCIA), the U.S. Supreme Court heard extended arguments Wednesday on fundamental questions entangling the biosimilar pathway.
- Following positive CHMP review, Biomarin scores FDA approval for Batten disease therapy
- Gottlieb makes it through committee, now on to the full Senate
- Mismatch endometrial bid proper fit for Tesaro's PD-1; study goes pivotal
- Eidos armed with $27M to seek 'essence' of amyloid pathology
- Industry applauds TGA's overhaul of orphan drug ...
- Samsung wins first U.S. biosimilar approval as FDA clears Renflexis
- Epimab nabs $25M to develop its bispecifics pipeline in China
- Aiming to eliminate hepatitis, WHO chronicles a daunting scourge
- Evidence for link between newer HCV therapies and liver cancer mixed
- HCV drug access remains varied and oft-restricte...
The Huntington's disease (HD) community was cheered this month by FDA approval of Austedo (deutetrabenazine), the deuterated tetrabenazine analogue from Teva Pharmaceutical Industries Ltd., to treat chorea, the involuntary, random and sudden, twisting and/or writhing movements associated with HD. (See BioWorld Today, April 5, 2017.)
Novel analogues of a class of antibacterial compounds isolated from soil bacteria could lead to the development of urgently needed new treatments for tuberculosis (TB), according to the findings of a study led by Australian researchers at the University of Sydney.
Worldwide, TB causes more deaths than any other infectious disease including HIV/AIDs. According to the WHO, there were an estimated 10.4 million new cases of TB and 1.8 million deaths in 2015, with 60 percent of all new cases occurring in Asia.READ MORE »
- Molecular structure may hold key to neurodegenerative diseases »
- SMA treatments can bring joy of the mundane »
- STRIVE heralds arrival of new migraine options »
- Tough forms of MS may yield to new approaches »
- High-dose chemo helps cancer vaccine »
- New target identified for treating TNBCs »
- Kissing cousins enable human knockout studies »
- Antisense oligonucleotides ameliorate ataxia, ALS »
- Researchers confirm reversal of cellular aging »
- Scientists don’t do politics … until nowApril 24, 2017 | 12:03 PM | Posted by: Nuala Moran
- Myth busters take on drug prices, or do they? April 04, 2017 | 1:35 AM | Posted by: Mari Serebrov
- Is ‘what the patient pays’ the right barometer for pricing drugs?January 26, 2017 | 5:08 PM | Posted by: Mari Serebrov
- Yes, there’s a doctor in the House (and Senate)January 04, 2017 | 12:21 AM | Posted by: Mari Serebrov
- Time for fa-la-la with BioWorld’s 10th annual Holiday Gift GuideDecember 02, 2016 | 8:43 PM | Posted by: Marie Powers
Partners in Focus
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST